The European Medicines Agency has begun reviewing EU marketing authorization applications (MAAs) for a new batch of medicines, including one for MenABCWY, Pfizer’s investigational pentavalent meningococcal vaccine, which, if approved, could provide the broadest serogroup coverage of any meningococcal vaccine.
MenABCWY, according to Pfizer, could also help simplify the meningococcal vaccination schedule. By combining the components from the company’s two...








